Chest Conference4 2009
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
368
On Slideshare
351
From Embeds
17
Number of Embeds
2

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 17

http://quantiferon.blogspot.com 16
http://www.quantiferon.blogspot.com 1

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Chest Conference TB Update Case Presentation Ramin Khashayar, MD April 7, 2009
  • 2. Presentation of the Case
    • 63 y.o. woman with a long standing diagnosis of U.C. treated with moderate to large doses of oral corticosteroid
    • Pt developed increasing cough and had a CXR and chest CT scan done as part of the work up
    • CXR revealed a new RUL infiltrate
  • 3. Presentation of the Case
    • Chest CT confirmed the presence of RUL infiltrate without associated LAD or pleural effusions
    • She reported 2 week h/o of low grade fevers and mild night sweats but no wt loss
    • There was no hemptysis
  • 4. Presentation of the Case
    • Laboratory testing was otherwise negative
    • TST was negative (no controls done)
    • Patient lives in W.C but had an extensive travel history in Asia and Africa
    • She denies know TB exposure and had not traveled in fungal endemic areas
  • 5. Presentation of the Case
    • She was seen in the office 3 days ahead of a planned air travel to Hawaii
  • 6. TB overview
    • Approxiamtely 1/3 of the work population had LTBI
    • An estiamted 10 million people worlwide have active TB
    • 2 million people a year die of tuberculosis
  • 7. TB overview
    • In the US, foreign-born persons from high TB risk areas have a 10-fold increased risk of developing TB
    • The risk of TB is highest in first five years after arrival but continues to be higher throughout their lives
    • The risk of TB in immigrant who travel back to the country of origin is higher than their cohort who don’t travel back
  • 8. TB overview
    • CDC recommend targeted screening for immigrants from high risk countries especially during the first five years after arrival
    • Local Health department recommend the use if IGRA (QuantiFERON-TB Gold assay) as this is more specific in people vaccinated with BCG
  • 9. QuantiFERON-TB Gold assay
    • One of three IGRAs, and one approved by FDA and available at JM (sent out to Sacto county lab)
    • It required heparinized fresh whole blood that needs to be tested within 12 hour as it requires viable lymphocytes
  • 10. QuantiFERON-TB Gold assay
    • Whole blood aliquots are mixed with two MTB (ESAT-6 and CFP-10) antigens, negative control mixture (saline) and a positive control mixture (mitogen) for 16-24 h
    • If the lymphocytes react to MTB antigen, they release gamma interferon that can be measures and compared to the negative and positive control samples and resultes as positive, nagative or indeterminate
  • 11. QuantiFERON-TB Gold assay
    • The major advantage of the test is lack of cross reactivity with BCG, or non-tuberculosis mycobacteria
    • It is also a one step test that does not require a second visit
    • It requires an expert lab as it is a biological test and can be subject to variability
  • 12. QuantiFERON-TB Gold assay
    • It requires fresh heparinized blood
    • It’s performance in children and immuno-compromized host (HIV/ steroids) is not known
    • Hard to study as TST itself is a poorly sensitive and non-specific test
  • 13. QuantiFERON-TB Gold assay
    • In one study, comparing two types of IGRA with TST, TST was found to be less sensitive than IGRA in HIV, liver transplant and hematologic malignancy patients (15-18% vs 10% positive rates)*
    • * Richeldi et al, Chest, April 2, 2009
  • 14. QuantiFERON-TB Gold assay
    • A study of 44 suspected pulmonary and 21 extrapulmonary TB pts, found QFT-G to be 75% and 76% sensitive vs 68% and 62% for TST*
    • *Ak et al, Jon. J. Infec. Dis., 2009
  • 15. QuantiFERON-TB Gold assay
    • In one study, 90 pts underwent bronchoscopic evaluation for TB
    • 28 had proven TB, 52 did not
    • In TB pts QFT-G was positive in 79%, TST in 57%
    • *Kobashi et al, Internal Medicine, 2007
  • 16. QuantiFERON-TB Gold assay
    • Locally, we quote a 20% false negative rate.
    • The sensitivity is probably higher that TST, and it is not complicated by BCG vaccination
    • The false negative pts with QFT-g and TST do not overlap
    • One study suggested that if both tests are negative, TB is even less likely (?)
  • 17. TB Review, PT classification
    • TB1: No evidence of TB or LTBI
    • TB2: LTBI
    • TB3: Active TB
    • TB4: Old TB (CXR w/o change for 3 mo, no clinical or microbiologic suspicion for TB
    • TB5: TB suspect, high prob or low prob
  • 18. TB